December 18, 2019
Volunteers were randomly assigned to receive either
The relevance of vaccine protection in rhesus monkeys to clinical efficacy in
humans remains unclear. China
compound film filling machines Manufacturers There is no definitive
immunological measurement that is known to predict protection against HIV-1 in
humans. (Photo: Pixabay) Scientists have developed a new vaccine that can safely
and effectively elicit immune response against a wide variety of HIV strains, an
advance which may help prevent the deadly infection in the future.
Researchers,
including those from Harvard Medical School in the US, found that the 'mosaic'
vaccine, created by combining pieces of different HIV viruses, is well-tolerated
and generated comparable and robust immune responses against HIV in healthy
adults and rhesus monkeys."
These results represent an important milestone," said
Dan Barouch, the lead author of the study published in The Lancet journal."This
study demonstrates that the mosaic Ad26 prime, Ad26 plus gp140 boost HIV vaccine
candidate induced robust immune responses in humans and monkeys with comparable
magnitude, kinetics, phenotype, and durability and also provided 67 per cent
protection against viral challenge in monkeys," said Barouch.Nearly 37 million
people worldwide are living with HIV/AIDS, with an estimated 1.8 million new
cases every year. A safe and effective preventative vaccine is urgently needed
to curb the HIV pandemic, the researchers said.A key hurdle to HIV vaccine
development has been the lack of direct comparability between clinical trials
and preclinical studies, the they said.To address these methodological issues,
the scientists evaluated the leading mosaic adenovirus serotype 26 (Ad26)-based
HIV-1 vaccine candidates in parallel clinical and pre-clinical studies to
identify the optimal HIV vaccine regimen to advance into clinical efficacy
trials.The trial recruited 393 healthy, HIV-uninfected adults (aged 18-50 years)
from 12 clinics in east Africa, South Africa, Thailand, and the US.
Volunteers
were randomly assigned to receive either one of seven vaccine combinations or a
placebo, and were given four vaccinations over the course of 48 weeks.To
stimulate, or 'prime', an initial immune response, each volunteer received an
intramuscular injection of Ad26.Mos.HIV at the start of the study and again 12
weeks later.
The vaccine containing 'mosaic' HIV Env/Gag/Pol antigens was created
from many HIV strains, delivered using a non-replicating common-cold virus
(Ad26).Results showed that all vaccine regimens tested were capable of
generating anti-HIV immune responses in healthy individuals and were well
tolerated, with similar numbers of local and systemic reactions reported in all
groups, most of which were mild-to-moderate in severity.The researchers also
noted several limitations, including the fact that that the relevance of vaccine
protection in rhesus monkeys to clinical efficacy in humans remains
unclear.
There is no definitive immunological measurement that is known to
predict protection against HIV-1 in humans, they said."These results should be
interpreted cautiously. The challenges in the development of an HIV vaccine are
unprecedented, and the ability to induce HIV-specific immune responses does not
necessarily indicate that a vaccine will protect humans from HIV infection,
Barouch said.
Posted by: packagingmachinery at
03:22 AM
| No Comments
| Add Comment
Post contains 488 words, total size 4 kb.
12kb generated in CPU 0.0086, elapsed 0.0302 seconds.
33 queries taking 0.0237 seconds, 46 records returned.
Powered by Minx 1.1.6c-pink.
33 queries taking 0.0237 seconds, 46 records returned.
Powered by Minx 1.1.6c-pink.